DE06803587T1 - Reines rocuroniumbromid - Google Patents

Reines rocuroniumbromid Download PDF

Info

Publication number
DE06803587T1
DE06803587T1 DE06803587T DE06803587T DE06803587T1 DE 06803587 T1 DE06803587 T1 DE 06803587T1 DE 06803587 T DE06803587 T DE 06803587T DE 06803587 T DE06803587 T DE 06803587T DE 06803587 T1 DE06803587 T1 DE 06803587T1
Authority
DE
Germany
Prior art keywords
rocuronium bromide
hplc
impurity
measured
less
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
DE06803587T
Other languages
English (en)
Inventor
Juana Araceli Coyoacan MENDEZ
Marco A. De La Mora
Alejandro Guillen
Hugo Herrera
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sicor Inc
Original Assignee
Sicor Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37757118&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE06803587(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Sicor Inc filed Critical Sicor Inc
Publication of DE06803587T1 publication Critical patent/DE06803587T1/de
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
    • C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
    • C07D451/04—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof with hetero atoms directly attached in position 3 of the 8-azabicyclo [3.2.1] octane or in position 7 of the 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring system
    • C07D451/06—Oxygen atoms
    • C07D451/10—Oxygen atoms acylated by aliphatic or araliphatic carboxylic acids, e.g. atropine, scopolamine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J43/00—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton
    • C07J43/003—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton not condensed
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J43/00—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Gyroscopes (AREA)

Abstract

Rocuroniumbromid, Verbindung I:

Claims (8)

  1. Rocuroniumbromid, Verbindung I:
    Figure 00010001
    mit einem potentiometrischen Test von 99% bis 101% in Essigsäure und Perchlorsäure mit einem Bereich von weniger als etwa 0,2% an Verunreinigung A, gemessen durch HPLC, und mit wenigstens einem der Lösungsmittel Ethylether und Dichlormethan in einer Menge von gleich oder weniger als etwa 850 ppm bzw. 600 ppm.
  2. Rocuroniumbromid nach Anspruch 1 mit einem Bereich von weniger als etwa 0,1% an Verunreinigung A, gemessen durch HPLC.
  3. Rocuroniumbromid nach einem der Ansprüche 1 oder 2 mit einem Bereich von etwa 0,1% bis etwa 0,02% an Verunreinigung A, gemessen durch HPLC.
  4. Rocuroniumbromid nach einem der Ansprüche 1 bis 3 mit einem Bereich von etwa 0,07% bis etwa 0,02% an Verunreinigung A, gemessen durch HPLC.
  5. Rocuroniumbromid nach einem der Ansprüche 1 bis 4 mit einem gesamten Lösungsmittelgehalt von weniger als 2000 ppm.
  6. Pharmazeutische Formulierung, welche das Rocuroniumbromid nach einem der Ansprüche 1 bis 5 und wenigstens einen pharmazeutisch verträglichen Hilfsstoff umfaßt.
  7. Verfahren zur Herstellung der pharmazeutischen Formulierung nach Anspruch 6, welches das Mischen des Rocuroniumbromids und des wenigstens einen pharmazeutisch verträglichen Hilfsstoffs umfaßt.
  8. Verwendung der pharmazeutischen Formulierung nach Anspruch 6 bei der Herstellung eines Medikaments für die Muskelentspannung.
DE06803587T 2005-09-13 2006-09-14 Reines rocuroniumbromid Pending DE06803587T1 (de)

Applications Claiming Priority (10)

Application Number Priority Date Filing Date Title
US71712205P 2005-09-13 2005-09-13
US75267105P 2005-12-19 2005-12-19
US752671P 2005-12-19
US75243505P 2005-12-20 2005-12-20
US752435P 2005-12-20
US77632206P 2006-02-23 2006-02-23
US776322P 2006-02-23
US78474606P 2006-03-21 2006-03-21
US784746P 2006-03-21
PCT/US2006/035828 WO2007073424A1 (en) 2005-09-13 2006-09-13 Pure rocuronium bromide

Publications (1)

Publication Number Publication Date
DE06803587T1 true DE06803587T1 (de) 2007-11-22

Family

ID=37757118

Family Applications (2)

Application Number Title Priority Date Filing Date
DE602006019822T Active DE602006019822D1 (de) 2005-09-13 2006-09-13 Reines rocuroniumbromid
DE06803587T Pending DE06803587T1 (de) 2005-09-13 2006-09-14 Reines rocuroniumbromid

Family Applications Before (1)

Application Number Title Priority Date Filing Date
DE602006019822T Active DE602006019822D1 (de) 2005-09-13 2006-09-13 Reines rocuroniumbromid

Country Status (13)

Country Link
US (4) US7642246B2 (de)
EP (4) EP2119723A1 (de)
JP (2) JP2008522983A (de)
KR (3) KR20100095013A (de)
CN (1) CN101687905A (de)
AT (1) ATE496933T1 (de)
BR (1) BRPI0605937A2 (de)
CA (2) CA2618272A1 (de)
DE (2) DE602006019822D1 (de)
ES (1) ES2288811T5 (de)
MX (1) MX2008000933A (de)
TW (2) TW200804410A (de)
WO (2) WO2007033348A2 (de)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2004311544A1 (en) * 2003-11-17 2005-07-21 Merck & Cie Crystalline forms of (6R) -L-erythro-tetrahydrobiopterin dihydrochloride
ES2370829T3 (es) * 2004-06-02 2011-12-23 Sandoz Ag Producto intermedio de meropenem en forma cristalina.
JP2008522983A (ja) 2005-09-13 2008-07-03 シコール インコーポレイティド ロクロニウムブロミドの合成方法
EP1928826B1 (de) * 2005-09-21 2013-04-24 4Sc Ag Sulfonylpyrrolhydrochloridsalze als inhibitoren von histondeacetylasen
EA014905B1 (ru) * 2005-10-31 2011-02-28 Янссен Фармацевтика Н.В. Новый способ получения пиперазинильных производных бензамида
MX2008016008A (es) * 2006-06-16 2009-01-16 Lundbeck & Co As H Formas cristalinas de 4-[2-(4-metilfenilsulfonil)-fenil] piperidina con inhibicion combinada de la recaptacion de serotonina y norepinefrina para el tratamiento del dolor neuropatico.
BRPI0717394A2 (pt) * 2006-10-27 2013-10-15 Signal Pharm Llc Forma cristalina, composição farmacêutica, forma de dosagem unitária única, método para tratar ou prevenir uma doença ou condição, e, processo para preparar um composto
GB2445746A (en) * 2007-01-17 2008-07-23 Texcontor Ets Use of carbonated water as a solvent for freeze drying, and method of purification comprising dissolution of material in carbonated water and freeze drying
WO2009016648A2 (en) * 2007-07-30 2009-02-05 Gland Pharma Limited Process for the preparation of rocuronium bromide and intermediate thereof
EP2085397A1 (de) * 2008-01-21 2009-08-05 Esteve Quimica, S.A. Kristalline Form von Abacavir
US7935817B2 (en) * 2008-03-31 2011-05-03 Apotex Pharmachem Inc. Salt form and cocrystals of adefovir dipivoxil and processes for preparation thereof
AR071318A1 (es) * 2008-04-15 2010-06-09 Basilea Pharmaceutica Ag Benzhidril ester del acido (6r,7r)-7-{2-(5-amino-[1,2,4]tiadiazol-3-il)-2-[(z)-tritiloxiimino]-acetilamino}-3-[(r)-1'-terc-butoxicarbonil-2-oxo-[1,3']bipirrolidinil-(3e)-ilidenometil]-8-oxo-5-tia-1-aza-biciclo[4.2.0]oct-2-eno-2-carboxilico cristalino; su elaboracion y uso
US8097719B2 (en) * 2008-07-15 2012-01-17 Genesen Labs Meropenem intermediate in novel crystalline form and a method of manufacture of meropenem
KR101016608B1 (ko) * 2008-12-03 2011-02-22 (주) 성운파마코피아 로큐로니움 브로마이드의 제조방법
CN101863948B (zh) * 2009-04-17 2013-07-24 重庆医药工业研究院有限责任公司 高纯度(2β,3α,5α,16β,17β)-2-(4-吗啉基)-16-(1-吡咯烷基)-雄甾烷-3,17-二醇或其组合物及其制备方法
KR101713453B1 (ko) 2010-03-12 2017-03-07 오메로스 코포레이션 Pde10 억제제 및 관련 조성물 및 방법
CN101824066B (zh) * 2010-04-08 2012-06-13 浙江仙琚制药股份有限公司 制备罗库溴铵中间体化合物结晶物的方法
WO2012030957A2 (en) * 2010-09-01 2012-03-08 Arena Pharmaceuticals, Inc. Non-hygroscopic salts of 5-ht2c agonists
CN103119051B (zh) * 2011-01-26 2015-09-23 浙江华海药业股份有限公司 罗库溴铵的制备方法
US9024013B2 (en) 2011-04-25 2015-05-05 Zhejiang Huahai Pharmaceutical Co., Ltd Method for purifying rocuronium bromide
CN103930419B (zh) * 2011-09-30 2016-06-01 广东东阳光药业有限公司 阿齐沙坦的晶型及其制备方法
CN102633858A (zh) * 2012-03-06 2012-08-15 连云港贵科药业有限公司 罗库溴铵关键中间体2α,3α-环氧-16β-(1-吡咯烷基)-5α-雄甾烷-17羟基的制备方法
CN103588847A (zh) * 2012-08-17 2014-02-19 重庆医药工业研究院有限责任公司 一种罗库溴铵中间体的制备方法
WO2015012332A1 (ja) * 2013-07-24 2015-01-29 田辺三菱製薬株式会社 眼科疾患治療剤
CN103435674B (zh) * 2013-09-09 2015-05-06 山东新华制药股份有限公司 高纯度、高稳定性罗库溴铵的制备方法
CN103435675B (zh) * 2013-09-25 2015-05-13 宜昌人福药业有限责任公司 一种甾类肌松药的精制方法
NZ630810A (en) 2014-04-28 2016-03-31 Omeros Corp Processes and intermediates for the preparation of a pde10 inhibitor
NZ716462A (en) * 2014-04-28 2017-11-24 Omeros Corp Optically active pde10 inhibitor
JP2016121073A (ja) * 2014-12-24 2016-07-07 ニプロ株式会社 注射剤用医薬組成物の製造方法
AU2016250843A1 (en) 2015-04-24 2017-10-12 Omeros Corporation PDE10 inhibitors and related compositions and methods
JP2018535969A (ja) 2015-11-04 2018-12-06 オメロス コーポレーション Ｐｄｅ１０阻害剤の固体状態形態
CN106950314A (zh) * 2017-04-17 2017-07-14 南京健友生化制药股份有限公司 一种检测罗库溴铵或其注射液中烯丙基溴含量的方法
CN107312055A (zh) * 2017-06-08 2017-11-03 江苏正大清江制药有限公司 一种罗库溴铵新的制备方法
CA3074831A1 (en) * 2017-09-07 2019-03-14 Athenex HK Innovative Limited Solid forms of 2-(5-(4-(2-morpholinoethoxy)phenyl)pyridin-2-yl)-n-benzylacetamide
CN108676052B (zh) * 2018-08-16 2020-05-22 北京市新里程医药科技有限公司 一种罗库溴铵的制备方法及其药物组合物
CN109053855B (zh) * 2018-10-08 2020-02-14 台州仙琚药业有限公司 一种16β-四氢吡咯基雄甾-2α-环氧-17-酮的合成方法
CN111196835B (zh) * 2019-12-27 2021-10-26 成都新恒创药业有限公司 一种罗库溴铵晶型
CN111303230B (zh) * 2020-03-09 2021-07-13 中国食品药品检定研究院 一种黄体酮共晶物及其制备方法和用途
CN114088842B (zh) * 2021-11-19 2023-03-21 江苏正济药业股份有限公司 一种罗库溴铵中间体及杂质的检测方法

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1138605A (en) * 1965-02-19 1969-01-01 Organon Labor Ltd Improvements in or relating to new 2-ß,16-ß-diamino-androstanes
IE53463B1 (en) * 1981-06-15 1988-11-23 Akzo Nv Mono-and bisquaternary ammonium derivatives of 2 beta,16 beta-d-amino-5 alpha-androstane derivatives and pharmaceutical preparations containing same
GB8708886D0 (en) 1987-04-14 1987-05-20 Akzo Nv 2beta-morpholino-androstane derivatives
GB8709565D0 (en) 1987-04-23 1987-05-28 Akzo Nv 2beta,16beta-diaminoandrostanes
HU210076B (en) * 1992-11-02 1995-01-30 Tuba Process for producing androstane derivatives substituted with quaternisaeted amino group in 16-position and for producing pharmaceutical compositions containing them
IT1277700B1 (it) 1995-12-22 1997-11-11 Poli Ind Chimica Spa Processo di preparazione di 2-beta, 16-beta-diamino 3-alfa, 17-beta- diacilossi 5-alfaandrostani, bloccanti neuromuscolari a struttura
JP3440741B2 (ja) * 1997-03-04 2003-08-25 戸田工業株式会社 磁気カード用マグネトプランバイト型フェライト粒子粉末
DE19903894A1 (de) 1999-02-01 2000-08-03 Scheiber Gerd Arzneimittelkombination zur Muskelrelaxation in Anaestesie und Intensivmedizin
WO2005068487A2 (en) 2004-01-15 2005-07-28 Chemagis Ltd. Processes for the preparation of rocuronium bromide and intermediates thereof
US20060058275A1 (en) * 2004-07-15 2006-03-16 Oded Friedman Processes for preparing stabilized, highly pure rocuronium bromide
US20060058276A1 (en) * 2004-07-15 2006-03-16 Oded Friedman Processes for the preparation and purification of rocuronium bromide
US20060009485A1 (en) * 2005-06-23 2006-01-12 Chemagis Ltd Method of reprocessing quaternary ammonium-containing neuromuscular blocking agents
JP2008522983A (ja) * 2005-09-13 2008-07-03 シコール インコーポレイティド ロクロニウムブロミドの合成方法
KR20070075390A (ko) 2007-06-25 2007-07-18 진철 금나노입자를 이용한 근이완제 Rocuronium의 효능개선 및작열감해소

Also Published As

Publication number Publication date
WO2007033348A3 (en) 2008-02-28
US20070265237A1 (en) 2007-11-15
BRPI0605937A2 (pt) 2009-05-26
US7569687B2 (en) 2009-08-04
CA2617816A1 (en) 2007-03-22
KR20100095013A (ko) 2010-08-27
US20090137794A1 (en) 2009-05-28
US7642246B2 (en) 2010-01-05
EP1924592A2 (de) 2008-05-28
ATE496933T1 (de) 2011-02-15
EP1828221A1 (de) 2007-09-05
EP1828221B2 (de) 2013-12-25
TW200804409A (en) 2008-01-16
EP1828221B1 (de) 2011-01-26
WO2007033348A2 (en) 2007-03-22
WO2007073424A1 (en) 2007-06-28
ES2288811T1 (es) 2008-02-01
KR20070085703A (ko) 2007-08-27
EP2107066A3 (de) 2009-10-21
DE602006019822D1 (de) 2011-03-10
TW200804410A (en) 2008-01-16
JP2008519865A (ja) 2008-06-12
EP2107066A2 (de) 2009-10-07
CN101687905A (zh) 2010-03-31
EP2119723A1 (de) 2009-11-18
US20070117975A1 (en) 2007-05-24
JP2008522983A (ja) 2008-07-03
ES2288811T3 (es) 2011-04-20
MX2008000933A (es) 2008-03-26
ES2288811T5 (es) 2014-02-24
KR20080025763A (ko) 2008-03-21
US20090093632A1 (en) 2009-04-09
WO2007073424A8 (en) 2008-02-07
CA2618272A1 (en) 2007-06-28

Similar Documents

Publication Publication Date Title
DE06803587T1 (de) Reines rocuroniumbromid
USRE49110E1 (en) Pharmaceutical formulations containing dopamine receptor ligands
DE69333605T2 (de) Stabile injizierbare Paclitaxel Lösung
EP2295422A3 (de) Glucopyranosylsubstituierte Benzolderivate, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung
EP1192212B1 (de) Verwendung von cyclohexanpolycarbonsäuren als weichmacher zur herstellung toxikologisch günstig zu bewertender kunststoffe
DE19742981B4 (de) Durch ROMP härtbare Dentalmassen
DE69607749T2 (de) Analoge des calcitonin aus lachs, ihre herstellung und ihre verwendung als medizin und als analytische reagentien
EP3834829A3 (de) Kompatibles solut oder solutgemisch (vorzugsweise ectoin bzw. ectoin-derivate) zur verwendung bei der prävention oder behandlung von krankheiten mit barrieredefekten in epithelgeweben
LU83982A1 (de) Platin-diamin-komplexe,ein verfahren zu ihrer herstellung,ein verfahren zur herstellung eines arzneimittels unter einsatz eines derartigen platin-diamin-komplexes fuer die behandlung von krebs sowie das dabei erhaltene arzneimittel
DE3752109T2 (de) Entzündungshemmende Mittel
DE102015013939A1 (de) Verfahren zur Herstellung von Gadotersäure (Gd-DOTA)- Komplexen
DE69332636T2 (de) Antidepressiv und gegen die Parkinsonsche Krankheit wirkende Verbindungen
CN103553996B (zh) 抗胆碱药物组合物
US20220082543A1 (en) Analysis method of 3-methyl-1-phenyl-2-pyrazolin-5-one active pharmaceutical ingredient, treatment for amyotrophic lateral sclerosis, inhibition of progression of amyotrophic lateral sclerosis, and method of producing medicament containing 3-methyl-1-phenyl-2-pyrazolin-5-one active pharmaceutical ingredient
DE112011103711B4 (de) Caspofungin-Analogon und Herstellungsverfahren dafür und Verwendungen desselben
CH632411A5 (de) Verwendung von 2-brom-2-chlor-1,1,1-trifluorethan-d als komponente in einem anesthetischen mittel.
DE102005038376A1 (de) Verfahren zur destillativen Abtrennung von Piperazin aus einem Ethylendiamin-Piperazin-Gemisch
Jbara et al. Assessing The Quantity And Quality Of Ozonated Olive Oil And Studying Its Shelf-Life Stability
DE69925301T2 (de) Zusammensetzung von riluzol und alpha-tocopherol
DE3639225A1 (de) Verwendung von 5-(subst. phenyl)-oxazolidinonderiaten als psychopharmaka
DE60310717T2 (de) Teicoplanin-Zubereitung mit verbesserter antibiotischer Wirkung
Horlacher Pyridomycin as lead for new antituberculosis agents and synthesis of hypermodified epothilone A analogs
DE3586781T2 (de) Behandlungsverfahren gegen hohen blutdruck bei wirbeltieren.
DE2154867A1 (de) Neue tricyclische Derivate von aliphatischen omega-Aminoalkoholen und Verfahren zu deren Herstellung
EP2818477B1 (de) L-lysyl-l-glutamyl-l-tryptophan zur korrektur des stoffwechselsyndroms